[HTML][HTML] HIV in pregnancy: Mother-to-child transmission, pharmacotherapy, and toxicity

L Cerveny, P Murthi, F Staud - … et Biophysica Acta (BBA)-Molecular Basis of …, 2021 - Elsevier
An estimated 1.3 million pregnant women were living with HIV in 2018. HIV infection is
associated with adverse pregnancy outcomes and all HIV-positive pregnant women …

In-depth analysis of physiologically based pharmacokinetic (PBPK) modeling utilization in different application fields using text mining tools

A Krstevska, J Đuriš, S Ibrić, S Cvijić - Pharmaceutics, 2022 - mdpi.com
In the past decade, only a small number of papers have elaborated on the application of
physiologically based pharmacokinetic (PBPK) modeling across different areas. In this …

Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV

N Mulligan, BM Best, J Wang, EV Capparelli, A Stek… - Aids, 2018 - journals.lww.com
Objective: To evaluate dolutegravir pharmacokinetics during pregnancy compared with
postpartum and in infant washout samples after delivery. Design: Ongoing, nonrandomized …

Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV

JD Momper, BM Best, J Wang, EV Capparelli, A Stek… - Aids, 2018 - journals.lww.com
Objective: To evaluate elvitegravir and cobicistat pharmacokinetics during pregnancy
compared with postpartum and in infant washout samples after delivery. Design …

Maternal endothelial dysfunction in HIV-associated preeclampsia comorbid with COVID-19: a review

N Naidoo, J Moodley, T Naicker - Hypertension Research, 2021 - nature.com
This review assesses markers of endothelial dysfunction (ED) associated with the maternal
syndrome of preeclampsia (PE). We evaluate the role of antiretroviral therapy (ART) in …

Sustained aviraemia despite anti-retroviral therapy non-adherence in male children following in utero hiv transmission

N Bengu, G Cromhout, E Adland, K Govender… - Nature Medicine, 2024 - nature.com
Following sporadic reports of post-treatment control of HIV in children who initiated
combination antiretroviral therapy (cART) early, we here prospectively studied 284 very …

Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically‐Based Pharmacokinetic Modeling

JJM Freriksen, S Schalkwijk, AP Colbers… - Clinical …, 2020 - Wiley Online Library
Antiretroviral therapy during pregnancy reduces the risk of vertical HIV‐1 transmission.
However, drug dosing is challenging as pharmacokinetics (PK) may be altered during …

Low levels of tenofovir in breast milk support breastfeeding in HBV-infected mothers treated with tenofovir disoproxil fumarate

S Li, J Jin, Y Jiang, J Shi, X Jiang, N Lin, Z Ma - International Journal of …, 2023 - Elsevier
Objective Tenofovir disoproxil fumarate (TDF) is recommended for the prevention of mother-
to-infant transmission of the hepatitis B virus (HBV). This study investigated the safety of …

Risk of birth defects and perinatal outcomes in HIV-infected women exposed to integrase strand inhibitors during pregnancy

J Sibiude, J Le Chenadec, L Mandelbrot, C Dollfus… - Aids, 2021 - journals.lww.com
Objectives: Following an alert on neural tube defects and dolutegravir, we sought to
evaluate if the exposure integrase strand transfer inhibitors (INSTIs) at conception was …

Placental transfer and tissue accumulation of dolutegravir in the ex vivo human cotyledon perfusion model

L Mandelbrot, PF Ceccaldi, D Duro, M Lê, L Pencolé… - PloS one, 2019 - journals.plos.org
Objective To determine the transplacental pharmacokinetics of the HIV integrase inhibitor
dolutegravir. Study design Maternal-to-fetal transfer across the term human placenta was …